Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells

Molecular Cancer Therapeutics

Volumn 7, Issue 2, 2008, Pages 398-406

  Huguet, Florence ^a,b,d   Giocanti, Nicole ^a,b   Hennequin, Christophe ^a,b,e   Croisy, Martine ^a,c   Touboul, Emmanuel ^d   Favaudon, Vincent ^a,b,f  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d HÔPITAL TENON   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f INSERM U612   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE 1; DNA; IMATINIB; PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAD51 PROTEIN; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROSCOPE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RADIATION; RADIATION RESPONSE; RADIOSENSITIVITY; WESTERN BLOTTING;

APOPTOSIS; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; G2 PHASE; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NECROSIS; PIPERAZINES; PYRIMIDINES; RADIATION-SENSITIZING AGENTS; S PHASE;

EID: 39749184139     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2023     Document Type: Article

References (48)

1. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 1999;9:179-86.
2. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44.
3. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
4. Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-Imatinib era. Leuk Res 2004;28 Suppl 1:21-8.
5. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
6. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118-25.
7. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001;20:5826-35.
8. Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 2002;21:7137-46.
9. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 2003;31:11-7.
10. + cells. Blood 2004;103:3167-74.
11. Parmar S, Katsoulidis E, Verma A, et al. Role of the p38 map kinase pathway in the generation of the effects of Imatinib mesylate (STI571) in BCR-ABL expressing cells. J Biol Chem 2004;279:25345-52.
12. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047-53.
13. Keeshan K, Cotter TG, McKenna SL. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia 2002;16:1725-34.
14. Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002;22:4189-201.
15. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002;21:8591-604.
16. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001;8:795-806.
17. Dierov J, Dierova R, Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 2004;5:275-85.
18. Deutsch E, Dugray A, Abdul-Karim B, et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001;97:2084-90.
19. Deutsch E, Jarrousse S, Buet D, et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003;101:4583-8.
20. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
21. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938-42.
22. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
23. Uemura N, Griffin JD. The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. Blood 2000;96:3294-5.
24. Russell JS, Brady K, Burgan WE, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003;63:7377-83.
25. Podtcheko A, Ohtsuru A, Namba H, et al. Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells. Radiat Res 2006;165:35-42.
26. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB, Traxler P. Phenylamino-pyrimidine (PAP)-derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg Med Chem Lett 1996;6:1221-6.
27. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB. Potent and selective inhibitors of the Abl-kinases: phenylamino-pyrimidine (PAP)-derivatives. Bioorg Med Chem Lett 1997;7:187-92.
28. Drexler HG, MacLeod RA, Uphoff CC. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res 1999;23:207-15.
29. Piret B, Schoonbroodt S, Piette J. The ATM protein is required for sustained activation of NF-κB following DNA damage. Oncogene 1999; 18:2261-71.
30. Kawano T, Horiguchi-Yamada J, Saito S, et al. Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. Leuk Res 2004;28:623-9.
31. Demarcq C, Bastian G, Remvikos Y. BrdUrd/DNA flow cytometry analysis demonstrates cis-diamminedichloroplatinum (II)-induced multiple cell-cycle modifications on human lung carcinoma cells. Cytometry 1992;13:416-22.
32. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002;8:2976-84.
33. Park J, Kim S, Oh C, Yoon SS, Lee D, Kim Y. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with Imatinib mesylate. Biochem Biophys Res Commun 2005;336:942-51.
34. Jacquel A, Herrant M, Legros L, et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 2003;17:2160-2.
35. Okada M, Adachi S, Imai T, et al. A novel mechanism for Imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 2004;103:2299-307.
36. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000;96:2269-76.
37. Ptasznik A, Urbanowska E, Chinta S, et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med 2002;196:667-78.
38. Kharbanda S, Saleem A, Yuan ZM, et al. Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2. Cancer Res 1996;56:3617-21.
39. Geng L, Shinohara ET, Kim D, et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 2006;64:263-71.
40. Holdhoff M, Kreuzer KA, Appelt C, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005;34:181-5.
41. Jacobberger JW, Sramkoski RM, Frisa PS, et al. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry 2003;54:75-88.
42. Park JI, Jeong JS, Han JY, et al. Hydroxyurea induces a senescence-like change of K562 human erythroleukemia cell. J Cancer Res Clin Oncol 2000;126:455-60.
43. Riordan FA, Bravery CA, Mengubas K, et al. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or γ-irradiation of bcr/abl-positive leukaemia cells. Oncogene 1998;16:1533-42.
44. Jeong SJ, Jin YH, Moon CW, et al. Protein tyrosine kinase inhibitors modulate radiosensitivity and radiation-induced apoptosis in K562 cells. Radiat Res 2001;156:751-60.
45. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996;56:3589-96.
46. Decaudin D, de Crémoux P, Sastre X, et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 2005;113:849-56.
47. Maulik G, Bharti A, Khan E, Broderick RJ, Kijima T, Salgia R. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. J Environ Pathol Toxicol Oncol 2004;23:237-51.
48. Aye MT, Seguin JA, McBurney JP. Erythroid and granulocytic colony growth in cultures supplemented with human serum lipoproteins. J Cell Physiol 1979;99:233-8.